This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1162 entries already.
Agomab Therapeutics NV from Ghent, Belgium, today announced it has extended its Series B financing round with an additional close of $40.5 million (38.4 million), bringing the total Series B […]
Navinci Diagnostics AB, a Swedish life science company formerly known as Olink developing innovative tools for spatial proteomics research, announces the closing of SEK 90 million financing. The round was […]
In a deal worth around USD435m Swiss ADC therapeutics grants Swedish Orphan Biovitrum (SOBI) the rights to market freshly approved Zynlonta outside the US.
The European Circular Bioeconomy Fund (ECBF) expands its industrial biotechnology portfolio by joining the financing Series B of danish Biosyntia ApS. Biosyntia is a precision fermentation company focused on bio-based […]
Large CDMO Lonza to build a new large-scale, commercial drug product facility including fill and finish to support customers across the entire product life cycle in Switzerland, investment of CHF500m.
Evotec, pharma giant Boehringer Ingelheim, and IVD specialist bioMérieux have launched a 40m joint venture to fight Antimicrobial Resistance (AMR).
French drugmaker Pierre Fabre Médicaments will pay $75m for an exclusive licence to to commercialise Urovant Sciences drug vibegron for the treatment of overactive bladder in Europe.
German mRNA vaccine developer CureVac, whose COVID-19 vaccine was not effective, on Monday sued BioNTech/Pfizer for infringement of four patents.
Shares of French drugmaker Ipsen fell by 4.4% at Euronext Paris after the company announced to take over US cancer specialist Epizyme Inc. for $247m.
At the end of the TWB Start-up day, which was attended by more than 200 biotech professionals, two industrial biotechnology companies were awarded prizes worth 50,000.